Filter
27
Filtered Results: 27
Text search:
Global
Antibiotic
Research
&
Development
Partnership
GARDP
Featured
Recommendations
4
New Publications
5
Language
Document type
Studies & Reports
9
No document type
7
Guidelines
4
Resource Platforms
2
Strategic & Response Plan
2
Manuals
1
Training Material
1
Situation Updates
1
Countries / Regions
Global
2
South Africa
2
Nepal
1
Cambodia
1
Asia
1
Uganda
1
Zambia
1
Authors & Publishers
Publication Years
Category
Pediatrics
2
Policies
2
Guidelines
2
Paediatrics
1
Vector Control
1
Disease Prevention & Control
1
Toolboxes
General
4
Studies
3
Country specific
2
Platforms and initiatives
2
Sustainable Development Goals
2
International
2
Local Action
1
Surveillance
1
Health Equity & Equality
1
Supporting tools
1
Research & Development
1
Country Specific
1
Biodiversity shift
1
Strategies
1
Waste Managment
1
Strategies & Roadmaps
1
Asia and Pacific
1
Stewardship
1
General Public
1
Assessment
1
AMR
1
Reports & Studies
1
Meeting Report
27–30 June 2017 Manila, Philippines
This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ...
Diese Broschüre möchte dazu beitragen, dass möglichst viele Menschen die Ergebnisse öffentlich finanzierter Forschung nutzen können.
Accessed April 2014
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac...
The focus of the current quarterly edition of Eurohealth (from the European Observatory on Health Systems and Policies) is Antimicrobial Resistance (AMR) and contains the following articles:
• Strengthening implementation of AMR national action plans
• Fostering clinical developmen...
Sepsis contributes significantly to preventable mortality and is the final common pathway to death for severe infectious diseases; it can also arise as a complication of injuries and non-communicable diseases.
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we ...
Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach. This policy guidance responds to that demand from Member States and is anchored in public health guiding principles in the human health sect...
Antimicrobial Resistance Resource Platform
recommended
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections ha...
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent...
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
